GlassScriptPhysician profile
Alban De Schutter
NPI 1134434988
$9,277.71
in general payments reported to CMS, 2019-2025
29 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $554 · 2021: $241 · 2022: $1,428 · 2023: $2,305 · 2024: $1,370 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410 · Travel and Lodging: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.15 |
| Travel and Lodging | $1,496.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,002.10 | 2019-2025 | Optis, Aveir, Gallant |
| Boston Scientific Corporation | $3,366.70 | 2019-2025 | Angiojet Ultra 5000a, Lux-Dx Insertable Cardiac Monitor, General - Balloon Catheters |
| Novartis Pharmaceuticals Corporation | $203.82 | 2019-2025 | |
| Biotronik INC. | $189.31 | 2024-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Philips North America LLC | $162.82 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Bq9) Coronary Ivus |
| Abiomed | $144.91 | 2022-2023 | Impella |
| Janssen Pharmaceuticals, INC | $143.80 | 2019-2020 | |
| Edwards Lifesciences Corporation | $135.32 | 2020-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $102.41 | 2023-2024 | Concertotm |
| Regeneron Healthcare Solutions, INC. | $83.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $77.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.48 | 2019-2020 | |
| Shockwave Medical, INC | $71.70 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $60.53 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $50.79 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.53 | 2019-2021 | |
| Cardiovascular Systems INC. | $44.09 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.52 | 2019-2020 | |
| Amarin Pharma, INC. | $38.51 | 2019-2020 | |
| Amgen INC. | $38.21 | 2019-2022 | |
| Heartflow, INC. | $37.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.19 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $24.56 | 2021 | |
| Acadia Pharmaceuticals INC | $19.47 | 2019 | |
| Merck Sharp & Dohme LLC | $19.37 | 2022 | |
| Adamas Pharmaceuticals, INC. | $18.44 | 2019 | |
| Lundbeck LLC | $18.22 | 2019 | |
| United Therapeutics Corporation | $15.63 | 2024 | Orenitram |
| Portola Pharmaceuticals, LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alban De Schutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.